South Korean medical AI company Lunit announced on Monday that it will present seven studies using its AI biomarker platform Lunit Scope at the 2025 American Association for Cancer Research (AACR 2025), to be held in Chicago from April 25 to 30.
The seven presentations include previously disclosed joint studies with global pharmaceutical giants Genentech and AstraZeneca, such as the evaluation of the efficacy of the immunotherapy drug Tecentriq and AI-based prediction of EGFR mutations.
One of the key studies at the conference will focus on predicting the response to neoadjuvant immunochemotherapy in patients with salivary gland carcinoma (SGC), a rare cancer. The study combined Lunit Scope IO’s AI analysis and sequencing results with spatial transcriptomics technology using 10x Genomics’ Xenium platform, analyzing samples from 14 patients with SGC.
The researchers found that in patients with recurrence, genes associated with immune evasion and cancer metastasis were highly expressed, while the expression of CXCL9, a gene that induces tumor-infiltrating lymphocytes (TILs) and immune cell recruitment, was lower.
This study is significant in that it revealed the characteristics of the tumor microenvironment (TME) by integrating spatial transcriptomic analysis with Lunit Scope IO. It is expected to provide important scientific evidence for establishing immunotherapy strategies for rare cancers such as SGC.
Lunit will also present research results on AI-based prediction of transformation risk from non-small cell lung cancer (NSCLC) with EGFR mutations to small cell lung cancer (SCLC).
By analyzing tissue slides from 106 patients using AI, the researchers classified tumor heterogeneity at the cellular level and identified patients exhibiting morphological characteristics similar to those of SCLC.
The analysis showed that patients in the SCLC-like group had significantly smaller average nuclear sizes compared to others. These patients also showed a notably shorter progression-free survival (PFS) after treatment with tyrosine kinase inhibitors (TKIs). The rate of transformation into SCLC upon further testing was also higher.
This study is the first in the world to demonstrate that AI can identify patients at risk of SCLC transformation. It is expected to contribute to establishing more precise treatment strategies and improve prognostic prediction.
Lunit CEO Suh Beomseok indicated that the studies presented at AACR 2025 demonstrate Lunit Scope’s capability to offer practical insights for treating rare and hard-to-treat cancers. He further noted the company’s commitment to leading personalized cancer treatment by establishing new standards through AI-based analysis.
Meanwhile, Lunit is participating in the AACR for the seventh consecutive year, solidifying its presence at one of the world’s top three cancer conferences alongside ASCO and ESMO. Through its continued participation, Lunit has consistently proven the clinical efficacy and research scalability of Lunit Scope.